These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 877065)

  • 41. [56 recent pulmonary tuberculosis cases treated with combined rifampicin-isoniazid in a controlled experiment].
    Constans P; Morin Y; Saint-Paul M; Bonnaud G; Coury C; Bariéty M
    Rev Tuberc Pneumol (Paris); 1969 Mar; 33(2):145-62. PubMed ID: 4916251
    [No Abstract]   [Full Text] [Related]  

  • 42. [A clinical study on the chemotherapy for pulmonary tuberculosis in diabetics].
    Kawabata S; Funakoshi M; Kameda K
    Kekkaku; 1983 Jan; 58(1):25-31. PubMed ID: 6842930
    [No Abstract]   [Full Text] [Related]  

  • 43. [Simultaneous study of the induction effect of rifampicin and the phenotype for acetylation of isoniazid in 21 patients with tuberculosis undergoing a combination treatment].
    Chailleux E; Ordronneau J; Le Normand Y; Kergueris MF; Larousse C
    Rev Fr Mal Respir; 1980; 8(3):219-24. PubMed ID: 7187065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of pleural and pulmonary tuberculosis by drug combinations including rifampicin. Early results].
    Cornudella R; Garcia-Besada JA; Castellano A
    Rev Clin Esp; 1972 Jul; 126(1):59-64. PubMed ID: 5080189
    [No Abstract]   [Full Text] [Related]  

  • 45. [In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
    Nowak D; Radenbach D; Magnussen H
    Pneumologie; 1990 Feb; 44 Suppl 1():497-8. PubMed ID: 2114634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Experimental and clinical studies of rifampicin in tuberculosis.
    Konno K; Oizumi K; Hayashi I; Oka S
    Sci Rep Res Inst Tohoku Univ Med; 1970 Dec; 17(3):110-20. PubMed ID: 5004309
    [No Abstract]   [Full Text] [Related]  

  • 47. [L-transformation of the mycobacterial population in the process of treating patients with newly detected destructive pulmonary tuberculosis].
    Khomenko AG; Karachunskiĭ MA; Dorozhkova IR; Chukanov VI; Balta IuE
    Probl Tuberk; 1980 Feb; (2):18-23. PubMed ID: 6769110
    [No Abstract]   [Full Text] [Related]  

  • 48. [Results of the use of rifampicin and ethambutol in complex treatment of chronic destructive pulmonary tuberculosis].
    Alimov ShA; Stoianovskiĭ EA
    Probl Tuberk; 1976; 3():27-31. PubMed ID: 967851
    [No Abstract]   [Full Text] [Related]  

  • 49. [Prognosis of isoniazid-resistant patients of pulmonary tuberculosis].
    Yoshida F; Liu C
    Kekkaku; 1987 Jan; 62(1):17-24. PubMed ID: 3573507
    [No Abstract]   [Full Text] [Related]  

  • 50. [Studies of serum rifampicin concentrations].
    Takamoto M; Shinoda A; Kondou H; Nagano H; Kutsukake F; Mochizuki K; Taga Y; Yasutake T; Takano T; Hiro Y
    Kekkaku; 1986 Aug; 61(8):425-33. PubMed ID: 3784240
    [No Abstract]   [Full Text] [Related]  

  • 51. A cooperative study on rifampicin in original treatment of advanced pulmonary tuberculosis.
    Gyselen A; Verbist L; Cosemans J; Lacquet LM; Prignot J; Simon-Pouthier F; Debrabandere R; Devriendt J
    Acta Tuberc Pneumol Belg; 1969; 60(3):563-76. PubMed ID: 4906105
    [No Abstract]   [Full Text] [Related]  

  • 52. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Reactivation of pulmonary tuberculosis in patients treated with rifampicin and ethambutol].
    Kuznetsova ZA
    Probl Tuberk; 1985; (12):40-2. PubMed ID: 4095097
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparative efficacy of daily and intermittent chemotherapy with combinations of rifampicin and isoniazid in chronic murine tuberculosis, with particular reference to the prevention of relapses.
    Kradolfer F; Schnell R
    Arzneimittelforschung; 1973 Oct; 23(10):1465-6. PubMed ID: 4591315
    [No Abstract]   [Full Text] [Related]  

  • 55. [Efficiency of chemotherapy of destructive pulmonary tuberculosis, based on the results of rapid detection of drug sensitivity to isoniazid and rifampicin with the "TB-Biochip" test system].
    Kuz'min AV; Vasil'eva IA; Chernousova LN
    Probl Tuberk Bolezn Legk; 2006; (8):17-23. PubMed ID: 17002052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short course treatment with two drugs, isoniazid plus rifampicin for six months: a controlled clinical trial with two treatment regimens.
    Dubra FA
    Bull Int Union Tuberc; 1976; 51(1):61-4. PubMed ID: 1030314
    [No Abstract]   [Full Text] [Related]  

  • 57. [Maximum therapeutic efficiency of a guternary antitubercular preparation. (Streptomycin-ethambutol-rifampicin-isoniazid)].
    Almansa de Cara S
    Rev Clin Esp; 1972 May; 125(4):353-6. PubMed ID: 5080180
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract]   [Full Text] [Related]  

  • 59. [Rifampicin in the treatment of lung and kidney tuberculosis].
    Kraan JK; Mulder RJ; Mulder-De Jong MT; van Dijk B
    Ned Tijdschr Geneeskd; 1972 Jan; 116(1):9-15. PubMed ID: 4555064
    [No Abstract]   [Full Text] [Related]  

  • 60. [Light and electron microscopy studies of the liver in tuberculosis patients receiving rifampin and isoniazid].
    Pilheu JA; de Salvo MC; Koch O; Barcat JA
    Medicina (B Aires); 1981; 41(4):439-45. PubMed ID: 7339434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.